FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1470-1471 May 30, 1996 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Interferon alfa was approved as therapy for chronic hepatitis C in the United States in 1991 and for chronic hepatitis B in 1992. These approvals were based on the results of randomized, controlled trials showing that four-to-six-month courses of interferon induced sustained remissions of disease in a higher proportion of patients than was the case without therapy.^1,2,3,4,5 Since that time, more than a half-million people have been treated with interferon for chronic hepatitis. Nevertheless, nagging questions remain. Is interferon alfa effective in inducing permanent remissions? Does therapy change the natural history of chronic viral hepatitis? Does it improve survival?

The . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Price, N., Boxall, E. H. (2007). Treatment of children persistently infected with hepatitis B virus: seroconversion or suppression. J Antimicrob Chemother 60: 1189-1192 [Abstract] [Full Text]  
• Chang, K.-O., George, D. W. (2007). Bile Acids Promote the Expression of Hepatitis C Virus in Replicon-Harboring Cells. J. Virol. 81: 9633-9640 [Abstract] [Full Text]  
• Sandres, K., Dubois, M., Pasquier, C., Payen, J. L., Alric, L., Duffaut, M., Vinel, J. P., Pascal, J. P., Puel, J., Izopet, J. (2000). Genetic Heterogeneity of Hypervariable Region 1 of the Hepatitis C Virus (HCV) Genome and Sensitivity of HCV to Alpha Interferon Therapy. J. Virol. 74: 661-668 [Abstract] [Full Text]